Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective

Journal of Advanced Research

Volumn 7, Issue 3, 2016, Pages 391-402

  El Fishawy, Hussein ^a   Saadi, Gamal ^a   Hassaballa, May ^a   Hussein, Mohamed ^b   Doss, Wahid ^a   Ragab, Gaafar ^b   Barsoum, Rashad ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Chronic kidney Disease; Cryoglobulinemia; DAAs; Dialysis; Transplantation

Indexed keywords

EID: 84960444450     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2016.02.006     Document Type: Article

References (53)

1. van der Meer A.J., Veldt B.J., Feld J.J., Wedemeyer H., Dufour J.F., Lammert F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012, 308(24):2584-2593.
2. Cuadros D.F., Branscum A.J., Miller F.D., Abu-Raddad L.J. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications. Hepatology 2014, 60:1150-1159.
3. Gower E., Estes C., Blach S., Razavi-Shearer K., Razavi H.G.J. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014, 61(1 Suppl.):S45-S57.
4. Kamal S.M., Nasser I.A. Hepatitis C Genotype 4: what we know and what we don't yet know. Hepatology 2008, 47:1371-1383.
5. AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015, 62:932-954.
6. European Association for the Study of the Liver (EASL) recommendations on treatment of hepatitis C 2015. J Hepatol 2015, 63(1):199-236.
7. KDIGO Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008, (Suppl. 109):S1-S99.
8. Hepatitis C therapeutic registry and research network (HCV-TARGET). [accessed 15th Sep 2015]. http://www.hcvtarget.org/.
9. Øvrehus A.L.H., Blach S., Christensen P.B., Gerstoft J., Weis N., Krarup H., et al. P0714: impact of prioritizing treatment in a high resource setting-minimizing the burden of HCV related disease in 15 years. J Hepatol 2015, 62:S591-S592.
10. Fadem SZ. MDRD GFR calculator.[accessed 10th Feb 2016]. http://nephron.org/mdrd_gfr_si.
11. (No authors listed). eGFR using CKD-EPI. [accessed 10th Feb 2016]. https://qxmd.com/calculate/egfr-using-ckd-epi.
12. Arcaini L., Vallisa D., Rattotti S., et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014, 25(7):1404-1410.
13. Gisbert J.P., García-Buey L., Pajares J.M., Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutaneatarda: systematic review and meta-analysis. J Hepatol 2003, 39(4):620.
14. Takahashi K., Nishida N., Kawabata H., Haga H., Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012, 51(19):2745-2747.
15. Kawamura Y., Ikeda K., Arase Y., Yatsuji H., Sezaki H., Hosaka T., et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007, 120(12):1034-1041.
16. Sayiner Z.A., Haque U., Malik M.U., Gurakar A. Hepatitis C virus infection and its rheumatologic implications. Gastroenterol Hepatol (NY) 2014, 10(5):287-293.
17. Chiao E.Y., Engels E.A., Kramer J.R., Pietz K., Henderson L., Giordano T.P., Landgren O. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med 2009, 169(4):357-363.
18. Carrozzo M., Scally K. Oral manifestations of hepatitis C virus infection. World J Gastroenterol 2014, 20:7534-7543.
19. Baccaglini L., Thongprasom K., Carrozzo M., Bigby M. Urban legends series: lichen planus. Oral Dis 2013, 19:128-143.
20. Quartuccio L., Isola M., Corazza L., Ramos-Casals M., Retamozo S., Ragab G.M., et al. Validation of the AASLD-classification criteria for cryoglobulinaemic vasculitis. Rheumatology (Oxford) 2014, 53(12):2209-2213.
21. Doss W., Shiha G., Hassany M., Soliman R., Fouad R., Khairy M., et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 2015, 63(3):581-585.
22. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
23. Afdhal N., Zeuzem S., Kwo P., Chojkier M., Gitlin N., Puoti M., et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
24. Afdhal N., Reddy K.R., Nelson D.R., Lawitz E., Gordon S.C., Schiff E., et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
25. Kowdley K.V., Gordon S.C., Reddy K.R., Rossaro L., Bernstein D.E., Lawitz E., et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014, 370:1879-1888.
26. Abergel A., Loustaud-Ratti V., Metivier S., Jiang D., Kersey K., Knox S.J., et al. High SVR12 in ledipasvir/sofosbuvir treatment in patients with chronic genotype 4 and 5 HCV infection. J Hepatol 2015, S2:S219-S220.
27. Kohli A., Kapoor R., Sims Z., Nelson A., Sidharthan S., Lam B., et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof of concept phase 2a cohort study (NIAID SYNERGY (Genotype 4). Lancet Infect Dis 2015, 15(9):1049-1054.
28. Charlton M., Everson G.T., Flamm S.L., Kumar P., Landis C., Brown R.S., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015, 149:649-659.
29. Manns M., Forns X., Samuel D., Denning J., Arterburn S., Brandt-Sarif T., et al. G02: ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective solar 2 trial. J Hepatol 2015, 62:S187-S188.
30. Kwo P., Gitlin N., Nahass R., Bernstein D., Rojter S., Schiff E., et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J Hepatol 2015, 62(Suppl. 2):S270.
31. Lawitz E., Matusow G., DeJesus E., Yoshida E., Felizarta F., Ghalib R., et al. LP04: a phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or-experienced patients with chronic HCV genotype 1 infection and cirrhosis: Optimist-2. J Hepatol 2015, 62:S264-S265. 39.
32. Ram B.K., Frank C., Adam P., Cynthia L., Maria H., Lennox J., David R., et al. Efficacy and tolerability of half-dose sofosbuvir plus simeprevir in management of hepatitis C in patients with end-stage renal disease. J Hepatol 2015, 63:763-773.
33. Lawitz E., Sulkowski M.S., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A., et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study. Lancet 2014, 384(9956):1756-1765.
34. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I., et al. (AI444040 Study Group). Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370(3):211-221.
35. Welzel T.M., Herzer K., Ferenci P., Petersen J., Gschwantler M., Cornberg M., et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. J Hepatol 2015, 62:S619-S620.
36. Poordad F., Schiff E.R., Vierling J.M., Landis C., Fontana R.J., Yang R., et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study. J Hepatol 2015, 62(Suppl. 2):S261-S262.
37. Hézode C., Alric L., Brown A., Hassanein M., Rizzetto M., Buti M., et al. Randomized controlled trial of the NS5A inhibitor daclatasvir plus peginterferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther 2015.
38. Pol S., Reddy K.R., Baykal T., Hezode C., Hassanein T., Marcellin P., et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology 2014, 60:1129A.
39. Kwo P.Y., Mantry P.S., Coakley E., Te H.S., Vargas H.E., Brown R., et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014, 371(25):2375-2382.
40. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT-1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study. In: 50th Annual meeting of the European association for the study of the liver (EASL), Vienna, Austriam, vol. S257; 2015. p. 22-6.
41. Potthoff A., Berg T., Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009, 44:1487-1490.
42. Molina J.M., Orkin C., Iser D.M., Zamora F.X., Nelson M., Stephan C., et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015, 385:1098-1106.
43. Kiser J.J., Burton J.R., Everson G.T. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013, 10(10):596-606.
44. Scott G.M. Interferon: pharmacokinetics and toxicity. Philos Trans Roy Soc Lond B Biol Sci 1982, 299(1094):91-107.
45. University of Liverpool: Ribavirin PK fact sheet. [last accessed 16th October 2015]. http://www.hivdruginteractions.org/data/FactSheetImages/FactSheet_DrugID_112.pdf.
46. Full prescribing information for HARVONI. FDA-approved patient labeling issued: 2015. Reference ID: 3642283. U.S. 2015[Last reviewed on RxList: 4/7/2015]. http://www.gilead.com.
47. Mangia A., Clemente R., Musto P., Cascavilla I., La Floresta P., Sanpaolo G., et al. Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. Leukemia 1996, 10:1209-1213.
48. Khattab M.A., Eslam M., Alavian S.M. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepatitis Mon 2010, 10(4):258-269.
49. Shahin A.A., El-Desouky S.M., Zayed H.S. A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide. Clin Rheumatol 2011, 30:607-614.
50. Sansonno D., Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005, 5:227-236.
51. Cacoub P., Terrier B., Saadoun D. Hepatitis C virus-induced vasculitis: therapeutic options. Ann Rheum Dis 2014, 73:24-30.
52. Ramunni A., Brescia P. Double filtration plasmapheresis: an effective treatment of cryoglobulinemia. HCV infection and cryoglobulinemia 2012, 337-341. Springer, New York. F. Dammacco (Ed.).
53. Dammacco F., Sansonn D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013, 369:1035-1045.